Table S4. Hazard ratios with 95% confidence interval of models developed with reducing gene members of GMS in three nonsquamous non-small cell lung cancer cohorts.

Genes for modeling	PFS			OS	
	Training	**Internal validation**	**External validation**	**Training**	**Internal validation**
HGF-SMAD4-MLL3-KRAS-STK11-EGFR-PTPRD-TP53	**0.41 (0.28,0.61)**	**0.42 (0.25,0.69)**	**0.31 (0.20,0.48)**	**0.53 (0.32,0.89)**	**0.26 (0.13,0.54)**
HGF-SMAD4-MLL3-KRAS-STK11-EGFR-PTPRD	0.51 (0.35,0.75)	0.49 (0.3,0.8)	0.38 (0.25,0.59)	0.56 (0.34,0.91)	0.30 (0.15,0.6)
HGF-SMAD4-MLL3-KRAS-STK11-EGFR	0.58 (0.39,0.85)	0.54 (0.33,0.87)	0.50 (0.32,0.77)	0.65 (0.4,1.07)	0.33 (0.16,0.66)
HGF-SMAD4-MLL3-KRAS-STK11	0.60 (0.41,0.88)	0.54 (0.33,0.87)	0.50 (0.32,0.77)	0.65 (0.4,1.07)	0.33 (0.16,0.66)
HGF-SMAD4-MLL3-KRAS	0.65 (0.44,0.96)	0.86 (0.53,1.4)	0.67 (0.43,1.04)	0.77 (0.47,1.26)	0.62 (0.31,1.25)
HGF-SMAD4-MLL3	0.58 (0.35,0.95)	0.79 (0.43,1.43)	0.39 (0.23,0.66)	0.53 (0.28,0.99)	0.48 (0.19,1.19)

Abbreviations: GMS, genomic mutation signature; PFS, progression free survival; OS, overall survival.